Cargando…
Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070929/ https://www.ncbi.nlm.nih.gov/pubmed/37012693 http://dx.doi.org/10.1002/ctm2.1218 |
| _version_ | 1785019090141708288 |
|---|---|
| author | Hu, Jing Wu, Jiali Jin, Qihuang Zhang, Ling Shen, Ning Shu, Yiyang Cheng, Lu Zhang, Jian Hu, Guangyi Lv, Kangjia Jian, Qizhi Chen, Hui Zhang, Fang Sun, Xiaodong |
| author_facet | Hu, Jing Wu, Jiali Jin, Qihuang Zhang, Ling Shen, Ning Shu, Yiyang Cheng, Lu Zhang, Jian Hu, Guangyi Lv, Kangjia Jian, Qizhi Chen, Hui Zhang, Fang Sun, Xiaodong |
| author_sort | Hu, Jing |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10070929 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | John Wiley and Sons Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-100709292023-04-05 Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform Hu, Jing Wu, Jiali Jin, Qihuang Zhang, Ling Shen, Ning Shu, Yiyang Cheng, Lu Zhang, Jian Hu, Guangyi Lv, Kangjia Jian, Qizhi Chen, Hui Zhang, Fang Sun, Xiaodong Clin Transl Med Letter to the Editor John Wiley and Sons Inc. 2023-04-03 /pmc/articles/PMC10070929/ /pubmed/37012693 http://dx.doi.org/10.1002/ctm2.1218 Text en © 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Letter to the Editor Hu, Jing Wu, Jiali Jin, Qihuang Zhang, Ling Shen, Ning Shu, Yiyang Cheng, Lu Zhang, Jian Hu, Guangyi Lv, Kangjia Jian, Qizhi Chen, Hui Zhang, Fang Sun, Xiaodong Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform |
| title | Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform |
| title_full | Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform |
| title_fullStr | Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform |
| title_full_unstemmed | Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform |
| title_short | Repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform |
| title_sort | repurposing picropodophyllin as a potential thyroid eye disease treatment via delaying mitotic clonal expansion through a patient‐derived preclinical platform |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070929/ https://www.ncbi.nlm.nih.gov/pubmed/37012693 http://dx.doi.org/10.1002/ctm2.1218 |
| work_keys_str_mv | AT hujing repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT wujiali repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT jinqihuang repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT zhangling repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT shenning repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT shuyiyang repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT chenglu repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT zhangjian repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT huguangyi repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT lvkangjia repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT jianqizhi repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT chenhui repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT zhangfang repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform AT sunxiaodong repurposingpicropodophyllinasapotentialthyroideyediseasetreatmentviadelayingmitoticclonalexpansionthroughapatientderivedpreclinicalplatform |